An Overview of Biomarkers and Molecular Signatures in HCC
Abstract
:1. Introduction
2. Candidate Markers for Diagnosis
2.1. Serum DNA
2.2. RNA Expression
2.3. Serum Protein
2.3.1. AFP and AFP-mRNA
2.3.2. Hepatoma-specific Gamma-glutamyl Transferase (GGT) Isoenzyme
2.3.3. Transforming Growth Factor (TGF)-β1
2.3.4. Insulin-like Growth Factor (IGF)-II and Related Factors
2.3.5. Hepatocyte Growth Factor (HGF)
2.3.6. Heat Shock Proteins (HSPs)
2.3.7. Complement C3a
2.3.8. Glypican-3 (GPC3)
2.3.9. Squamous Cell Carcinoma Antigen (SCCA)
2.4. Immunohistochemistry (IHC) Markers
2.4.1. Hepatocyte Paraffin 1 (HepPar 1)
2.4.2. Polyclonal Carcinoembryonic Antigen (pCEA)
2.4.3. Glypican 3 (GPC-3)
2.4.4. MOC-31
2.4.5. α-Fetoprotein (AFP)
3. Candidate Markers for Prognosis
3.1. Chromosomal Alterations
3.2. DNA Methylation Profiles
3.3. Gene Expression Profiles
4. Conclusions
Acknowledgements
References
- Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 2001, 94, 153–156. [Google Scholar] [CrossRef]
- Shimozawa, N.; Hanazaki, K. Longterm prognosis after hepatic resection for small hepatocellular carcinoma. J. Am. Coll. Surg. 2004, 198, 356–365. [Google Scholar] [CrossRef]
- Soresi, M.; Magliarisi, C.; Campagna, P.; Leto, G.; Bonfissuto, G.; Riili, A.; Carroccio, A.; Sesti, R.; Tripi, S.; Montalto, G. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res. 2003, 23, 1747–1753. [Google Scholar]
- Zhang, Y.J.; Wu, H.C.; Shen, J.; Ahsan, H.; Tsai, W.Y.; Yang, H.I.; Wang, L.Y.; Chen, S.Y.; Chen, C.J.; Santella, R.M. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin. Cancer Res. 2007, 13, 2378–2384. [Google Scholar] [CrossRef]
- Wong, I.H.; Lo, Y.M.; Zhang, J.; Liew, C.T.; Ng, M.H.; Wong, N.; Lai, P.B.; Lau, W.Y.; Hjelm, N.M.; Johnson, P.J. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res. 1999, 59, 71–73. [Google Scholar]
- Chu, H.J.; Heo, J.; Seo, S.B.; Kim, G.H.; Kang, D.H.; Song, G.A.; Cho, M.; Yang, U.S. Detection of aberrant p16INK4A methylation in sera of patients with liver cirrhosis and hepatocellular carcinoma. J. Korean Med. Sci. 2004, 19, 83–86. [Google Scholar] [CrossRef]
- Kim, J.W.; Ye, Q.; Forgues, M.; Chen, Y.; Budhu, A.; Sime, J.; Hofseth, L.J.; Kaul, R.; Wang, X.W. Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology 2004, 39, 518–527. [Google Scholar] [CrossRef]
- Craig, J.R. Tumors of the liver. In Hepatology: A Textbook of Liver Disease, 3rd ed.; Zakim, D., Boyer, T., Eds.; Saunders: Philadelphia, PA, USA, 2003. [Google Scholar]
- Jia, H.L.; Ye, Q.H.; Qin, L.X.; Budhu, A.; Forgues, M.; Chen, Y.; Liu, Y.K.; Sun, H.C.; Wang, L.; Lu, H.Z.; Shen, F.; Tang, Z.Y.; Wang, X.W. Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin. Cancer Res. 2007, 13, 1133–1139. [Google Scholar] [CrossRef]
- Budhu, A.; Forgues, M.; Ye, Q.H.; Jia, H.L.; He, P.; Zanetti, K. A.; Kammula, U.S.; Chen, Y.; Qin, L.X.; Tang, Z.Y.; Wang, X.W. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006, 10, 99–111. [Google Scholar]
- Khien, V.V.; Mao, H.V.; Chinh, T.T.; Ha, P.T.; Bang, M.H.; Lac, B.V.; Hop, T.V.; Tuan, N.A.; Don, L.V.; Taketa, K.; Satomura, S. Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carcinoma. Int. J. Biol. Markers 2001, 16, 105–111. [Google Scholar]
- Yao, D.F.; Dong, Z.Z.; Yao, M. Specific molecular markers in hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 2007, 6, 241–247. [Google Scholar]
- Kamoto, T.; Satomura, S.; Yoshiki, T.; Okada, Y.; Henmi, F.; Nishiyama, H.; Kobayashi, T.; Terai, A.; Habuchi, T.; Ogawa, O. Lectin-reactive alpha-fetoprotein (AFP-L3%) curability and prediction of clinical course after treatment of non-seminomatous germ cell tumors. Jpn. J. Clin. Oncol. 2002, 32, 472–476. [Google Scholar] [CrossRef]
- Yoshida, S.; Kurokohchi, K.; Arima, K.; Masaki, T.; Hosomi, N.; Funaki, T.; Murota, M.; Kita, Y.; Watanabe, S.; Kuriyama, S. Clinical significance of lens culinaris agglutinin-reactive fraction of serum alpha-fetoprotein in patients with hepatocellular carcinoma. Int. J. Oncol. 2002, 20, 305–309. [Google Scholar]
- Cillo, U.; Navaglia, F.; Vitale, A.; Molari, A.; Basso, D.; Bassanello, M.; Brolese, A.; Zanus, G.; Montin, U.; D'Amico, F.; Ciarleglio, F.A.; Carraro, A.; Bridda, A.; Burra, P.; Carraro, P.; Plebani, M.; D'Amico, D.F. Clinical significance of alpha-fetoprotein mRNA in blood of patients with hepatocellular carcinoma. Clin. Chim. Acta 2004, 347, 129–138. [Google Scholar] [CrossRef]
- Yao, D.F.; Dong, Z.Z.; Yao, D.B.; Wu, X.H.; Wu, W.; Qiu, L.W.; Wang, H.M.; Meng, X.Y. Abnormal expression of hepatoma-derived gamma-glutamyltransferase subtyping and its early alteration for carcinogenesis of hepatocytes. Hepatobiliary Pancreat. Dis. Int. 2004, 3, 564–570. [Google Scholar]
- Yao, D.F.; Huang, Z.W.; Chen, S.Z.; Huang, J.F.; Lu, J.X.; Xiao, M.B.; Meng, X.Y. Diagnosis of hepatocellular carcinoma by quantitative detection of hepatoma-specific bands of serum gamma-glutamyltransferase. Am. J. Clin. Pathol. 1998, 110, 743–749. [Google Scholar]
- Pasche, B. Role of transforming growth factor beta in cancer. J. Cell Physiol. 2001, 186, 153–168. [Google Scholar] [CrossRef]
- Okumoto, K.; Hattori, E.; Tamura, K.; Kiso, S.; Watanabe, H.; Saito, K.; Saito, T.; Togashi, H.; Kawata, S. Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma. Liver Int. 2004, 24, 21–28. [Google Scholar] [CrossRef]
- Teicher, B.A. Malignant cells, directors of the malignant process: role of transforming growth factor-beta. Cancer Metastasis Rev. 2001, 20, 133–143. [Google Scholar] [CrossRef]
- Kim, Y.J.; Lee, H.S.; Im, J.P.; Min, B.H.; Kim, H.D.; Jeong, J.B.; Yoon, J.H.; Kim, C.Y.; Kim, M.S.; Kim, J.Y.; Jung, J.H.; Kim, L.H.; Park, B.L.; Shin, H.D. Association of transforming growth factor-beta1 gene polymorphisms with a hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. Exp. Mol. Med. 2003, 35, 196–202. [Google Scholar] [CrossRef]
- Scharf, J.G.; Dombrowski, F.; Ramadori, G. The IGF axis and hepatocarcinogenesis. Mol. Pathol. 2001, 54, 138–144. [Google Scholar] [CrossRef]
- Cantarini, M.C.; de la Monte, S.M.; Pang, M.; Tong, M.; D'Errico, A.; Trevisani, F.; Wands, J.R. Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology 2006, 44, 446–457. [Google Scholar]
- Wang, Z.; Ruan, Y.B.; Guan, Y.; Liu, S.H. Expression of IGF-II in early experimental hepatocellular carcinomas and its significance in early diagnosis. World J. Gastroenterol. 2003, 9, 267–270. [Google Scholar]
- Shiota, G.; Okano, J.; Kawasaki, H.; Kawamoto, T.; Nakamura, T. Serum hepatocyte growth factor levels in liver diseases: clinical implications. Hepatology 1995, 21, 106–112. [Google Scholar] [CrossRef]
- Breuhahn, K.; Longerich, T.; Schirmacher, P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 2006, 25, 3787–3800. [Google Scholar] [CrossRef]
- Vejchapipat, P.; Tangkijvanich, P.; Theamboonlers, A.; Chongsrisawat, V.; Chittmittrapap, S.; Poovorawan, Y. Association between serum hepatocyte growth factor and survival in untreated hepatocellular carcinoma. J. Gastroenterol. 2004, 39, 1182–1188. [Google Scholar] [CrossRef]
- Yamagamim, H.; Moriyama, M.; Matsumura, H.; Aoki, H.; Shimizu, T.; Saito, T.; Kaneko, M.; Shioda, A.; Tanaka, N.; Arakawa, Y. Serum concentrations of human hepatocyte growth factor is a useful indicator for predicting the occurrence of hepatocellular carcinomas in C-viral chronic liver diseases. Cancer 2002, 95, 824–834. [Google Scholar] [CrossRef]
- Srivastava, P.K. Immunotherapy for human cancer using heat shock protein-peptide complexes. Curr. Oncol. Rep. 2005, 7, 104–108. [Google Scholar] [CrossRef]
- Yao, D.F.; Wu, X.H.; Su, X.Q.; Yao, M.; Wu, W.; Qiu, L.W.; Zou, L.; Meng, X.Y. Abnormal expression of HSP gp96 associated with HBV replication in human hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 2006, 5, 381–386. [Google Scholar]
- Sakamoto, M.; Mori, T.; Masugi, Y.; Effendi, K.; Rie, I.; Du, W. Candidate molecular markers for histological diagnosis of early hepatocellular carcinoma. Intervirology 2008, 51, 42–45. [Google Scholar]
- Markiewski, M.M.; Mastellos, D.; Tudoran, R.; DeAngelis, R.A.; Strey, C.W.; Franchini, S.; Wetsel, R.A.; Erdei, A.; Lambris, J.D. C3a and C3b activation products of the third component of complement (C3) are critical for normal liver recovery after toxic injury. J. Immunol. 2004, 173, 747–754. [Google Scholar]
- Lee, I.N.; Chen, C.H.; Sheu, J.C.; Lee, H.S.; Huang, G.T.; Chen, D.S.; Yu, C.Y.; Wen, C.L.; Lu, F.J.; Chow, L.P. Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics 2006, 6, 2865–2873. [Google Scholar] [CrossRef]
- Capurro, M.; Wanless, I.R.; Sherman, M.; Deboer, G.; Shi, W.; Miyoshi, E.; Filmus, J. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003, 125, 89–97. [Google Scholar] [CrossRef]
- Hippo, Y.; Watanabe, K.; Watanabe, A.; Midorikawa, Y.; Yamamoto, S.; Ihara, S.; Tokita, S.; Iwanari, H.; Ito, Y.; Nakano, K.; Nezu, J.; Tsunoda, H.; Yoshino, T.; Ohizumi, I.; Tsuchiya, M.; Ohnishi, S.; Makuuchi, M.; Hamakubo, T.; Kodama, T.; Aburatani, H. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res. 2004, 64, 2418–2423. [Google Scholar] [CrossRef]
- Capurro, M.I.; Xiang, Y.Y.; Lobe, C.; Filmus, J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 2005, 65, 6245–6254. [Google Scholar] [CrossRef]
- Giannelli, G.; Marinosci, F.; Trerotoli, P.; Volpe, A.; Quaranta, M.; Dentico, P.; Antonaci, S. SCCA antigen combined with alpha-fetoprotein as serologic markers of HCC. Int. J. Cancer 2005, 117, 506–509. [Google Scholar] [CrossRef]
- Guido, M.; Roskams, T.; Pontisso, P.; Fassan, M.; Thung, S.N.; Giacomelli, L.; Sergio, A.; Farinati, F.; Cillo, U.; Rugge, M. Squamous cell carcinoma antigen in human liver carcinogenesis. J. Clin. Pathol. 2008, 61, 445–447. [Google Scholar] [CrossRef]
- Beneduce, L.; Castaldi, F.; Marino, M.; Quarta, S.; Ruvoletto, M.; Benvegnu, L.; Calabrese, F.; Gatta, A.; Pontisso, P.; Fassina, G. Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma. Cancer 2005, 103, 2558–2565. [Google Scholar] [CrossRef]
- Trerotoli, P.; Fransvea, E.; Angelotti, U.; Antonaci, G.; Lupo, L.; Mazzocca, A.; Mangia, A.; Antonaci, S.; Giannelli, G. Tissue expression of Squamous Cellular Carcinoma Antigen (SCCA) is inversely correlated to tumor size in HCC. Mol. Cancer 2009, 8, 29. [Google Scholar] [CrossRef]
- Kakar, S.; Gown, A.M.; Goodman, Z.D.; Ferrell, L.D. Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms. Arch. Pathol. Lab. Med. 2007, 131, 1648–1654. [Google Scholar]
- Varma, V.; Cohen, C. Immunohistochemical and molecular markers in the diagnosis of hepatocellular carcinoma. Adv. Anat. Pathol. 2004, 11, 239–249. [Google Scholar] [CrossRef]
- Lau, S.K.; Prakash, S.; Geller, S.A.; Alsabeh, R. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum. Pathol. 2002, 33, 1175–1181. [Google Scholar]
- Yamauchi, N.; Watanabe, A.; Hishinuma, M.; Ohashi, K.; Midorikawa, Y.; Morishita, Y.; Niki, T.; Shibahara, J.; Mori, M.; Makuuchi, M.; Hippo, Y.; Kodama, T.; Iwanari, H.; Aburatani, H.; Fukayama, M. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod. Pathol. 2005, 18, 1591–1598. [Google Scholar]
- Morrison, C.; Marsh, W., Jr.; Frankel, W.L. A comparison of CD10 to pCEA, MOC-31, and hepatocyte for the distinction of malignant tumors in the liver. Mod. Pathol. 2002, 15, 1279–1287. [Google Scholar] [CrossRef]
- Niemann, T.H.; Hughes, J.H.; De Young, B.R. MOC-31 aids in the differentiation of metastatic adenocarcinoma from hepatocellular carcinoma. Cancer 1999, 87, 295–298. [Google Scholar] [CrossRef]
- Lau, S.H.; Guan, X.Y. Cytogenetic and molecular genetic alterations in hepatocellular carcinoma. Acta Pharmacol. Sin. 2005, 26, 659–665. [Google Scholar] [CrossRef]
- Kim, T.M.; Yim, S.H.; Shin, S.H.; Xu, H.D.; Jung, Y.C.; Park, C.K.; Choi, J.Y.; Park, W.S.; Kwon, M.S.; Fiegler, H.; Carter, N.P.; Rhyu, M.G.; Chung, Y.J. Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q. Int. J. Cancer 2008, 123, 2808–2815. [Google Scholar] [CrossRef]
- Saelee, P.; Wongkham, S.; Bhudhisawasdi, V.; Sripa, B.; Chariyalertsak, S.; Petmitr, S. Allelic loss on chromosome 5q34 is associated with poor prognosis in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2008, 134, 1135–1141. [Google Scholar] [CrossRef]
- Poon, T.C.; Wong, N.; Lai, P.B.; Rattray, M.; Johnson, P.J.; Sung, J.J. A tumor progression model for hepatocellular carcinoma: bioinformatic analysis of genomic data. Gastroenterology 2006, 131, 1262–1270. [Google Scholar] [CrossRef]
- Jones, P.A.; Baylin, S.B. The epigenomics of cancer. Cell 2007, 128, 683–692. [Google Scholar] [CrossRef]
- Wilson, A.S.; Power, B.E.; Molloy, P.L. DNA hypomethylation and human diseases. Biochim. Biophys. Acta 2007, 1775, 138–162. [Google Scholar]
- Herman, J.G.; Baylin, S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 2003, 349, 2042–2054. [Google Scholar] [CrossRef]
- Chen, R.Z.; Pettersson, U.; Beard, C.; Jackson-Grusby, L.; Jaenisch, R. DNA hypomethylation leads to elevated mutation rates. Nature 1998, 395, 89–93. [Google Scholar] [CrossRef]
- Yoshiura, K.; Kanai, Y.; Ochiai, A.; Shimoyama, Y.; Sugimura, T.; Hirohashi, S. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc. Natl. Acad. Sci. USA 1995, 92, 7416–7419. [Google Scholar] [CrossRef]
- Kanai, Y.; Ushijima, S.; Hui, A.M.; Ochiai, A.; Tsuda, H.; Sakamoto, M.; Hirohashi, S. The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. Int. J. Cancer 1997, 71, 355–359. [Google Scholar] [CrossRef]
- Kanai, Y.; Hui, A.M.; Sun, L.; Ushijima, S.; Sakamoto, M.; Tsuda, H.; Hirohashi, S. DNA hypermethylation at the D17S5 locus and reduced HIC-1 mRNA expression are associated with hepatocarcinogenesis. Hepatology 1999, 29, 703–709. [Google Scholar] [CrossRef]
- Calvisi, D.F.; Ladu, S.; Gorden, A.; Farina, M.; Lee, J.S.; Conner, E.A.; Schroeder, I.; Factor, V.M.; Thorgeirsson, S.S. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J. Clin. Invest. 2007, 117, 2713–2722. [Google Scholar] [CrossRef]
- Gao, W.; Kondo, Y.; Shen, L.; Shimizu, Y.; Sano, T.; Yamao, K.; Natsume, A.; Goto, Y.; Ito, M.; Murakami, H.; Osada, H.; Zhang, J.; Issa, J.P.; Sekido, Y. Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. Carcinogenesis 2008, 29, 1901–1910. [Google Scholar] [CrossRef]
- Arai, E.; Ushijima, S.; Gotoh, M.; Ojima, H.; Kosuge, T.; Hosoda, F.; Shibata, T.; Kondo, T.; Yokoi, S.; Imoto, I.; Inazawa, J.; Hirohashi, S.; Kanai, Y. Genome-wide DNA methylation profiles in liver tissue at the precancerous stage and in hepatocellular carcinoma. Int. J. Cancer 2009, 125, 2854–2862. [Google Scholar] [CrossRef]
- Ye, Q.H.; Qin, L.X.; Forgues, M.; He, P.; Kim, J.W.; Peng, A.C.; Simon, R.; Li, Y.; Robles, A.I.; Chen, Y.; Ma, Z.C.; Wu, Z.Q.; Ye, S.L.; Liu, Y.K.; Tang, Z.Y.; Wang, X.W. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat. Med. 2003, 9, 416–423. [Google Scholar] [CrossRef]
- Lee, J.S.; Chu, I.S.; Heo, J.; Calvisi, D.F.; Sun, Z.; Roskams, T.; Durnez, A.; Demetris, A.J.; Thorgeirsson, S.S. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004, 40, 667–676. [Google Scholar] [CrossRef]
- Lee, J.S.; Heo, J.; Libbrecht, L.; Chu, I.S.; Kaposi-Novak, P.; Calvisi, D.F.; Mikaelyan, A.; Roberts, L.R.; Demetris, A.J.; Sun, Z.; Nevens, F.; Roskams, T.; Thorgeirsson, S.S. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat. Med. 2006, 12, 410–416. [Google Scholar] [CrossRef]
- Iizuka, N.; Oka, M.; Yamada-Okabe, H.; Nishida, M.; Maeda, Y.; Mori, N.; Takao, T.; Tamesa, T.; Tangoku, A.; Tabuchi, H.; Hamada, K.; Nakayama, H.; Ishitsuka, H.; Miyamoto, T.; Hirabayashi, A.; Uchimura, S.; Hamamoto, Y. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003, 361, 923–929. [Google Scholar] [CrossRef]
- Yamashita, T.; Forgues, M.; Wang, W.; Kim, J.W.; Ye, Q.; Jia, H.; Budhu, A.; Zanetti, K.A.; Chen, Y.; Qin, L.X.; Tang, Z.Y.; Wang, X.W. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008, 68, 1451–1461. [Google Scholar] [CrossRef]
- Micsenyi, A.; Tan, X.; Sneddon, T.; Luo, J.H.; Michalopoulos, G.K.; Monga, S.P. Beta-catenin is temporally regulated during normal liver development. Gastroenterology 2004, 126, 1134–1146. [Google Scholar] [CrossRef]
- Monga, S.P.; Monga, H.K.; Tan, X.; Mule, K.; Pediaditakis, P.; Michalopoulos, G.K. Beta-catenin antisense studies in embryonic liver cultures: Role in proliferation, apoptosis, and lineage specification. Gastroenterology 2003, 124, 202–216. [Google Scholar]
- Branda, M.; Wands, J.R. Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. Hepatology 2006, 43, 891–902. [Google Scholar] [CrossRef]
- Yamashita, T.; Budhu, A.; Forgues, M.; Wang, X.W. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res. 2007, 67, 10831–10839. [Google Scholar] [CrossRef]
- Budhu, A.; Jia, H.L.; Forgues, M.; Liu, C.G.; Goldstein, D.; Lam, A.; Zanetti, K.A.; Ye, Q.H.; Qin, L.X.; Croce, C.M.; Tang, Z.Y.; Wang, X.W. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008, 47, 897–907. [Google Scholar] [CrossRef]
© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Yim, S.-H.; Chung, Y.-J. An Overview of Biomarkers and Molecular Signatures in HCC. Cancers 2010, 2, 809-823. https://doi.org/10.3390/cancers2020809
Yim S-H, Chung Y-J. An Overview of Biomarkers and Molecular Signatures in HCC. Cancers. 2010; 2(2):809-823. https://doi.org/10.3390/cancers2020809
Chicago/Turabian StyleYim, Seon-Hee, and Yeun-Jun Chung. 2010. "An Overview of Biomarkers and Molecular Signatures in HCC" Cancers 2, no. 2: 809-823. https://doi.org/10.3390/cancers2020809